Delayed Emergence of HIV-1 Variants Resistant to 4′-Ethy Nyl-2-Fluoro-2′-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine,Tenofovir,Emtricitabine and BMS-986001
Free accessResearch articleFirst published online February, 2014
Delayed Emergence of HIV-1 Variants Resistant to 4′-Ethy Nyl-2-Fluoro-2′-Deoxyadenosine: Comparative Sequential Passage Study with Lamivudine,Tenofovir,Emtricitabine and BMS-986001
4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) contains an ethynyl moiety and the 3′-hydroxyl and exerts highly potent activity against various HIV type-1 (HIV-1) strains including multi-drug-resistant variants.
Methods
Comparative selection passages against EFdA, lamivudine (3TC), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) or BMS-986001 (Ed4T) were conducted using a mixture of 11 highly multi-drug-resistant clinical HIV-1 isolates (HIV11MIX) as a starting virus population.
Results
Before selection, HIV11MIX was sensitive to EFdA with a 50% inhibitory concentration (IC50) of 0.032 μM, less susceptible to TDF and Ed4T with IC50s of 0.57 and 2.6 μM, respectively, and highly resistant to 3TC and FTC with IC50s>10 μM. IC50s of TDF against HIV11MIX exposed to EFdA and TDF for 17 (HIV11MIXEFdA-P17) and 14 (HIV11MIXTDF-P14) passages were 8 and >10 μM, respectively, while EFdA remained active against HIV11MIXEFdA-P17 and HIV11MIXTDF-P14 with IC50s of 0.15 and 0.1 μM, respectively. Both selected variants were highly resistant against zidovudine, 3TC, Ed4T and FTC (IC50 values >10 μM).
Conclusions
The present data demonstrate that HIV11MIX developed resistance more rapidly against 3TC, FTC, TDF and Ed4T than against EFdA and that EFdA remained substantially active against TDF- and EFdA-selected variants. Thus, EFdA has a favourable resistance profile and represents a potentially promising new-generation nucleoside reverse transcriptase inhibitor.
References
1.
MitsuyaH., WeinholdK.J., FurmanP.A.3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A1985; 82: 7096–7100.
2.
De ClercqE.Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents2009; 33: 307–320.
3.
MaedaK., DasD., MitsuyaH.Development of antiviral therapeutics for HIV-1 infection and AIDS. In HallJ.C., HallB.J., CockerellC.J. (Editors). HIV/AIDS in the post-HAART era: manifestations, treatment & epidemiology. Shelton, CT: People's Medical Publishing House2011; pp. 900–937.
4.
TsibrisA.M., HirschM.S.Antiretroviral therapy in the clinic. J Virol2010; 84: 5458–5464.
5.
ChunT.W., FauciA.S.HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS2012; 26: 1261–1268.
6.
RichmanD.D., MargolisD.M., DelaneyM.The challenge of finding a cure for HIV infection. Science2009; 323: 1304–1307.
Menéndez-AriasL.Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res2013; 98: 93–120.
9.
Fernandez-FernandezB., Montoya-FerrerA., SanzA.B.Tenofovir nephrotoxicity: 2011 update. Aids Res Treat2011; 2011: 354908.
10.
MalikA., AbrahamP., MalikN.Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment – case report and review of literature. J Infect2005; 51: E61–E65.
11.
PowderlyW.G.Osteoporosis and bone health in HIV. Curr HIV/AIDS Rep2012; 9: 218–222.
12.
MillerM.D.K65R, TAMs and tenofovir. AIDS Rev2004; 6: 22–33.
13.
BrennerB.G., CoutsinosD.The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther2009; 3: 583–594.
14.
KawamotoA., KodamaE., SarafanosS.G.2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol2008; 40: 2410–2420.
15.
KodamaE.I., KohgoS., KitanoK.4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother2001; 45: 1539–1546.
16.
NakataH., AmanoM., KohY.Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine. Antimicrob Agents Chemother2007; 51: 2701–2708.
17.
Murphey-CorbM., RajakumarP., MichaelH.Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother2012; 56: 4707–4712.
18.
TamiyaS., MardyS., KavlickM.F., YoshimuraK., MitsuyaH.Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol2004; 78: 12030–12040.
19.
YoshimuraK., KatoR., YusaK.JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A1999; 96: 8675–8680.
20.
OhruiH.2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec2006; 6: 133–143.
21.
NitandaT., WangX., KumamotoH.Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob Agents Chemother2005; 49: 3355–3360.
22.
KohY., AmanoM., TowataT.In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol2010; 84: 11961–11969.
23.
MaedaK., YoshimuraK., ShibayamaS.Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem2001; 276: 35194–35200.
24.
AokiM., DanishM.L., Aoki-OgataH.The loss of protease dimerization inhibition activity of tipranavir (TPV) and its association with HIV-1 acquisition of resistance to TPV. J Virol2012; 86: 13384–13396.
25.
MoutouhL., CorbeilJ., RichmanD.D.Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A1996; 93: 6106–6111.
26.
YusaK., KavlickM.F., KosalaraksaP., MitsuyaH.HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antiviral Res1997; 36: 179–189.
27.
MichailidisE., MarchandB., KodamaE.N.Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem2009; 284: 35681–35691.
28.
HattoriS., IdeK., NakataH.Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob Agents Chemother2009; 53: 3887–3893.
29.
LauringA.S., AndinoR.Quasispecies theory and the behavior of RNA viruses. PLoS Pathog2010; 6: e1001005.
30.
De MeyerS., AzijnH., SurlerauxD.TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother2005; 49: 2314–2321.
31.
PovedaE., de MendozaC., Martin-CarboneroL.Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother2007; 60: 885–888.
32.
ImamichiT., SinhaT., ImamichiH.High-level resistance to 3′-azido-3′-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol2000; 74: 1023–1028.
33.
ImamichiT., BergS.C., ImamichiH.Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-to-Gly) at codon 69. J Virol2000; 74: 10958–10964.
34.
ImamichiT., MurphyM.A., ImamichiH., LaneH.C.Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistant profiles. J Virol2001; 75: 3988–3992.
35.
KisicM., MatamorosT., NevotM.Thymidine analogue excision and discrimination modulated by mutational complexes including single amino acid deletions of Asp-67 or Thr-69 in HIV-1 reverse transcriptase. J Biol Chem2011; 286: 20615–20624.
